Quick Comparison
| Mazdutide | Semaglutide | |
|---|---|---|
| Half-Life | 144-192 hours (6-8 days) | 168 hours (7 days) |
| Typical Dosage | Approved (China): 6-9 mg subcutaneous once weekly. Dose escalation over initial weeks starting at lower doses. Clinical trial doses ranged from 3-9 mg subcutaneous once weekly. | Weight management (Wegovy): 0.25 mg subcutaneous once weekly, escalating over 16 weeks to 2.4 mg once weekly. Diabetes (Ozempic): 0.25 mg subcutaneous once weekly, escalating to 1-2 mg once weekly. Oral (Rybelsus): 3 mg once daily for 30 days, then 7-14 mg once daily on an empty stomach. |
| Administration | Subcutaneous injection (weekly) | Subcutaneous injection (weekly). Oral formulation available (Rybelsus). |
| Research Papers | 27 papers | 30 papers |
| Categories |
Mechanism of Action
Mazdutide
Mazdutide is a dual-receptor agonist that activates both GLP-1 and glucagon receptors, combining appetite suppression with increased energy expenditure. The GLP-1 component functions similarly to other GLP-1 agonists — binding to receptors in the hypothalamus to reduce hunger, stimulating glucose-dependent insulin secretion from pancreatic beta cells, and slowing gastric motility to prolong post-meal satiety.
The glucagon receptor component distinguishes mazdutide from pure GLP-1 agonists. Glucagon binding in the liver activates adenylyl cyclase, increasing cAMP and activating protein kinase A, which phosphorylates key enzymes in fatty acid oxidation and ketogenesis. This drives the liver to burn stored fat as fuel rather than accumulate it — a mechanism with direct therapeutic relevance for patients with metabolic-associated fatty liver disease (MAFLD). In adipose tissue, glucagon signaling promotes lipolysis and may activate thermogenic programs in brown and beige fat cells.
The engineering challenge in dual GLP-1/glucagon agonists is balancing the hyperglycemic effect of glucagon against the glucose-lowering effects of GLP-1. Mazdutide achieves this by tuning the relative receptor affinities so that GLP-1-mediated insulin secretion offsets glucagon-driven glucose production, resulting in net glycemic improvement alongside enhanced fat oxidation and energy expenditure.
Semaglutide
Semaglutide is a modified version of the natural incretin hormone GLP-1, engineered with 94% structural homology to the native peptide. It binds to GLP-1 receptors expressed throughout the body, triggering a cascade of metabolic effects. In the pancreas, it stimulates glucose-dependent insulin secretion from beta cells while suppressing glucagon release from alpha cells, providing dual glycemic control that only activates when blood sugar is elevated.
In the central nervous system, semaglutide crosses the blood-brain barrier and acts on GLP-1 receptors in the hypothalamic arcuate nucleus and the brainstem's nucleus tractus solitarius. This suppresses appetite by modulating POMC/CART (anorexigenic) and NPY/AgRP (orexigenic) neuronal pathways. The result is a significant reduction in hunger, food cravings, and caloric intake — patients typically experience a fundamental shift in their relationship with food.
The extended duration of action comes from a C18 fatty di-acid chain attached at position 26 (lysine), which enables strong non-covalent binding to circulating albumin. This albumin binding shields semaglutide from DPP-4 enzymatic degradation — the process that destroys native GLP-1 within minutes — extending its half-life to approximately 7 days. Additionally, semaglutide slows gastric emptying through vagal nerve signaling, contributing to post-meal satiety and reduced glycemic excursions.
Risks & Safety
Mazdutide
Common
nausea, diarrhea, vomiting, reduced appetite, injection site reactions.
Serious
elevated liver enzymes, inflammation of the pancreas, gallstones.
Rare
thyroid concerns (seen with similar drugs in animals), severe liver damage.
Semaglutide
Common
nausea (30-45% of users), vomiting, diarrhea, constipation, stomach pain, headache.
Serious
inflammation of the pancreas (pancreatitis), gallstones, kidney problems from dehydration, loss of muscle mass alongside fat.
Rare
thyroid tumours seen in animal studies, severe allergic reactions.
Full Profiles
Mazdutide →
A weight loss injection that suppresses appetite while also boosting your metabolism and helping your liver burn fat. Approved in China for obesity in 2024, with up to 14% body weight loss in trials. It targets two hormones — GLP-1 (which reduces hunger) and glucagon (which increases calorie burning and liver fat breakdown). Particularly promising for people with fatty liver disease alongside obesity.
Semaglutide →
The most widely prescribed weight loss medication in the world, sold as Wegovy and Ozempic. Works by dramatically reducing appetite and food cravings — most people report feeling full much faster and losing interest in snacking. In clinical trials, patients lost an average of 15-17% of their body weight. Also available as a daily pill (Rybelsus). Originally developed for type 2 diabetes, it also helps control blood sugar levels.